



Uscom

ASX MEDIA RELEASE

Uscom and US Koneksa Extend Technology Partnership

As eHealth in Clinical Trials Grow, Companies Collaborate to Benefit Patients

SYDNEY, Australia, Wednesday 3rd November 2021: Uscom Limited (ASX code: UCM) (the **Company** or **Uscom**) today announced an extension of its ongoing partnership with digital biomarker leader Koneksa to develop and use Uscom's digital patient-monitoring technology for spirometers in clinical trials. The agreement between the companies relates to the direct wireless integration of data from the Uscom's SpiroSonic AIR device into Koneksa's proprietary platform.

Summary:

The Uscom R&D team has developed new high level spirometry algorithms and APPs to allow the breath to breath delivery of precise respiratory function data using the Uscom SpiroSonic AIR sensors. The SpiroSonic AIR technology utilises patent protected digital ultrasonic technology for improved accuracy and stability compared to conventional spirometry, and has a unique design to enhance disinfection and simplify patient operation.

Koneksa, a New York based medical technology leader, specialise in the collection and analysis of biometric data for pharmaceutical and biotechnology trials and require high resolution physiologic monitoring. The company specialises in digital monitoring of multiple physiologic parameters such as actigraphy, gait and balance, and vital signs such as body temperature, SpO2, BP, respiration, and heart rate, and has been using Uscom SpiroSonic digital spirometers for a number of years.

The agreement between Uscom and Koneksa relates to the wireless integration of new functions from the Uscom's SpiroSonic AIR device into Koneksa's proprietary platform that will advance their leadership in the clinical trial space.

Commentary:

Uscom Executive Chairman, Professor Rob Phillips said "The Spirosonic AIR is the most advanced technology of its kind, and we are delighted to expand our partnership with Koneksa as they continue to grow their leadership in the pharmaceutical and biotechnology trial space. This growing collaboration is a recognition of its expanding role in mHealth monitoring of lung function and demonstrates the increasing importance of digital health monitoring. Koneksa requires the most sensitive front-end sensors to generate accurate data for their proprietary platform, and have been using Uscom devices in their studies for several years. This agreement establishes the pathway for our devices to become a standard lung-function testing device, and to be adopted in many pharmaceutical trials going forward. Lung function is a critical clinical measure in asthma, COPD, and COVID – both long and short – among other conditions."



Uscom

ASX MEDIA RELEASE

About Uscom

Uscom Limited (UCM): An ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.

The USCOM 1A: A simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

The Uscom BP+: A supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension and pre-eclampsia, heart failure, intensive care, general practice and home care. The Uscom BP+ is supported by the proprietary **BP+ Reporter**, an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyse pulse pressure waves and generate summary reports.

Uscom SpiroSonic digital multi-path ultrasonic spirometers: High fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They require no calibration, are simple to disinfect, and are simple and accurate to use providing research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone apps and proprietary SpiroSonic software, **SpiroReporter**, with wireless interfacing to provide remote tele-monitoring of pulmonary disease. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, occupational lung disease and monitoring of pulmonary therapeutic compliance.

VENTITEST digital ultrasonic ventilator testing solution is a new system for testing ventilators. All ventilators require calibration to maintain the accuracy with which they measure the pressure, flow and volume of air they deliver. VENTITEST and VENTITEST-S, based on advanced SpiroSonic technology provides a testing solution that provides for simple and accurate testing, archiving, analysis and reporting to optimise ventilation performance.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Rob Phillips
Chairman

rob@uscom.com.au

Brett Crowley
Company Secretary

This announcement is approved for release to the ASX by the Board of Uscom Limited.